The UK aesthetic injectables market is worth over £400 million and is forecast to nearly double by 2030, according to Grand View Research. Botulinum toxin – anti-wrinkle treatment; holds the largest single share of that market. And demand from clients is not slowing. According to the BAAPS 2024 annual audit, Botox use by BAAPS member surgeons alone increased by 5%, while dermal fillers jumped 27% in the same year.